Medtronic, Hansen to present clinical trial data at VEITHSymposium

Medtronic (NYSE:MDT) and Hansen Medical (NSDQ:HNSN) said they are slated to present new clinical information at this year’s annual VEITHSymposium in New York City. Medtronic said today it plans to present 4-year subset data results from the ENGAGE global registry study of its Endurant AAA stent graft system. The trial analyzed patients with hostile neck anatomies treated with the abdominal aortic aneurysm stent graft system, the Fridley, Minn.-based company said. The company said it will present data in 9 separate presentations on its EndoAnchor system, which it obtained in its $110 million purchase of Aptus Endosystems in June. “Leveraging decades of clinical experiences and data, our core technologies for treating abdominal aortic aneurysm and descending thoracic disease, Endurant and Valiant product lines, have been proven in more than 280,000 patients globally. Our mission to improve patient outcomes drives our commitment to build on our success and invest in complementary innovative technology that will allow physicians to treat more complex aortic disease,” Medtronic aortic biz gm Daveen Chopra said in a press release. Medtronic is slated to present data on modified Valiant devices used to treat ascending arch disease, 1-year results from a feasibility trial of its Valiant Mona LSA branch thoracic stent graft system and initial experience data in treating thoracoabdominal with modified versions of the company’s stent grafts. Hansen Medical said its Magell...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Cardiovascular Catheters Clinical Trials Stent Grafts Stents Hansen Medical Inc. Medtronic Source Type: news